查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1942284

失眠症市场规模、份额、趋势和预测（按治疗类型、药物类别、分销管道和地区划分），2026-2034年

Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2025年全球失眠市场规模为55亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到68亿美元，2026年至2034年的复合年增长率（CAGR）为2.45%。北美目前占据市场主导地位，预计2025年将占据超过36.4%的市场。推动市场成长的关键因素包括：现代生活方式和压力导致失眠盛行率上升；诊断技术进步提高了诊断准确性；积极开展新型治疗方法的研究；医疗费用支出增加；数位化医疗解决方案的整合；策略性产业合作；以及消费者对非药物疗法的偏好日益增长。此外，先进的医疗环境、睡眠障碍的高盛行率以及创新治疗方法的应用也进一步推动了失眠市场份额的成长。

现代生活方式、压力和人口老化导致睡眠障碍病例增加，这是失眠市场的主要驱动因素。诊断技术的进步提高了诊断的准确性，而对新型治疗方法的研究则拓展了治疗选择。医疗保健成本的上升以及包括睡眠追踪应用程式和远端医疗在内的数位化医疗解决方案的普及，都在推动市场成长。例如，Emma-The Sleep Company 于 2024 年 3 月推出的「Emma Up」是一款创新的 AI 睡眠指导应用程序，它采用基于声音的睡眠追踪技术。该应用程式满足了超过 73% 用户改善睡眠品质的需求，并提供个人化分析以应对睡眠挑战。消费者对非药物疗法（例如失眠认知行为疗法）的需求以及政府的各项倡议，也为全球失眠市场带来了积极前景。

美国失眠市场的主要驱动因素是压力、久坐的生活方式和人口老化导致的睡眠障碍高发生率。人们对睡眠健康及其对整体健康影响的认识不断提高，推动了对有效治疗方法的需求。诊断工具和治疗方法的进步，特别是睡眠应用程式和远端医疗等数位健康技术，进一步体现了美国失眠市场的一些关键趋势。例如，SleepScore Labs于2024年10月发布了“Sleep.AI”，这是第一个基于实证医学的睡眠健康人工智慧平台，利用了超过5亿小时的睡眠数据和230多项研究成果。非药物疗法，特别是针对失眠的认知行为疗法（CBT），正受到消费者的青睐。此外，大规模的研究投入、不断上涨的医疗保健成本以及支持性的保险政策也在推动美国失眠市场的发展。

失眠市场趋势：

压力、焦虑和精神疾病呈上升趋势

sutoresu、不安、および精神疾患の発生率増加が市场に好影响を与えています。米国精神医学会が2024年ル2024年には成人の43％が202 3年と比较してより强い不安を感じたと报告しており、これは2023年の37％、2022年の32％から増加しています仕事のプラッシャー、デジタル机器による关注散漫、社会课题といった现代の生活様式は、広范な睡眠障碍害を引き起こしています。慢性的なsutoresuホルモンバransuに影响を与え、睡眠・覚醒サイクルを乱すことぁめめめめもすあぁぁめめめめめめめめめめめめめめめめぁめぁめぁ、ぁさらに、不安や忧郁症病は睡眠障碍害と存并することが医疗多く、的介入の需要を高めています。メンタルウェルネsuに対する社会意识の高まりは、より多くの人々が専门家の助けを求めるよう助し、睡眠薬や治疗の増加につながっています。制定薬企业は、sutoresu关连の不眠症に特化した、より安全で依存性の低い薬剤や认知行动治疗を开癁のすいます。在全球心理健康挑战日益严峻的背景下，心理健康与睡眠健康之间日益密切的联繫仍然是推动市场扩张的核心因素。

人口老化和睡眠障碍风险增加

全球人口老化是失眠市场成长的重要推动因素。根据世界卫生组织预测，到2030年，全球六分之一的人口将达到或超过60岁。老年人更容易受到与老龄化相关的生理变化、慢性疾病和药物副作用的影响，从而出现睡眠障碍。关节炎、心血管疾病和神经系统疾病等常常会扰乱正常的睡眠模式。此外，褪黑激素分泌会随着老龄化增长而减少，这使得老年人更难维持规律的睡眠週期。预期寿命的延长和健康意识的提高促使越来越多的老年人寻求睡眠相关问题的医疗帮助。这种人口结构的变化导致对处方药、行为疗法和天然助眠产品的需求不断增长。与老龄化相关的睡眠障碍是推动市场发展的关键因素之一，因为医疗保健机构正致力于提供针对老年人需求的整体睡眠管理方案。

数位生活风格和萤幕曝光量的增加

对电子设备的日益依赖和萤幕使用时间的延长为市场带来了有利前景。根据行业报告显示，到2024年第三季度，全球16至64岁的用户平均每天将在各种设备的萤幕前花费6小时38分钟。智慧型手机、平板电脑和电脑发出的蓝光会抑制褪黑激素的分泌，扰乱自然睡眠週期，导致入睡困难。远距办公、深夜娱乐活动和社交媒体的使用加剧了各个年龄层的这一问题。持续的线上状态和过度刺激会提升认知警觉性，阻碍充分休息。随着人们对电子设备引起的睡眠障碍的认识不断提高，消费者开始寻求助眠产品、行动应用程式和疗法来改善睡眠品质。製药和健康公司正透过褪黑激素补充剂、行为疗法和正念练习等方式来解决这一现代生活方式问题。萤幕生活方式的持续发展确保了临床和消费者健康市场对失眠治疗的稳定需求。

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测性调查方法

第三章执行摘要

第四章 引言

第五章 全球失眠市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 按治疗类型分類的市场区隔

  • 非药物疗法
    • 主要部分
      • 催眠疗法
      • 认知行为疗法
      • 医疗设备
      • 其他的
  • 药物治疗
    • 主要部分
      • 处方助眠药
      • 非处方助眠药

7. 按药物类别分類的市场细分

  • 抗忧郁症
  • 褪黑素拮抗剂
  • 苯二氮平类药物
  • 非苯二氮平类药物
  • Orexin拮抗剂
  • 其他的

第八章 按分销管道分類的市场细分

  • 医院药房
  • 零售药房
  • 药局
  • 网路药房

第九章 按地区分類的市场细分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章 价值链分析

第十二章 波特五力分析

第十三章：定价分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Aurobindo Pharma USA
    • Eisai Inc.
    • Idorsia Pharmaceuticals, Ltd
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc
    • Neurim Pharmaceuticals LTD
    • Pfizer Inc
    • Sanofi SA
Product Code: SR112026A6148

The global insomnia market size was valued at USD 5.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.8 Billion by 2034, exhibiting a CAGR of 2.45% during 2026-2034. North America currently dominates the market, holding a significant market share of over 36.4% in 2025. Increasing prevalence due to modern lifestyles and stress, advancements in diagnostic technologies enhancing accuracy, robust research into novel therapies, rising healthcare expenditures, integration of digital health solutions, strategic industry collaborations, and growing consumer preference for non-pharmacological treatments are some of the factors bolstering the market growth. In addition to this, advanced healthcare, high sleep disorder prevalence, and adoption of innovative treatments are further increasing the insomnia market share.

The key drivers in the insomnia market are increasing prevalence of sleep disorders due to modern lifestyles, stress, and aging populations. Advances in diagnostic technologies improve accuracy while research into novel therapies is increasing the treatment options. Increasing healthcare expenditures and the adoption of digital health solutions including sleep-tracking apps and telemedicine are fueling growth in the market. For instance, in March 2024, Emma Up launched by Emma - The Sleep Company is an innovative AI sleep coaching app featuring sound-based sleep tracking. It offers personalized insights to tackle sleep issues addressing over 73% of users' desire for better sleep quality. Consumer demand for non-pharmacological treatments like cognitive behavioral therapy for insomnia and government initiatives are also creating a positive insomnia market outlook across the world.

The key drivers in the United States insomnia market are the high prevalence of sleep disorders associated with stress, sedentary lifestyles and aging populations. Increased awareness of the importance of sleep health and its impact on overall well-being is driving demand for effective treatments. Advances in diagnostic tools and therapeutic options including digital health technologies like sleep apps and telemedicine further represent some of the key insomnia market trends in the country. For instance, in October 2024, SleepScore Labs launched Sleep.AI the first evidence-based AI platform for sleep health utilizing over 500 million hours of sleep data and insights from 230+ studies. Increasing non-pharmacological treatments especially cognitive behavioral therapy for insomnia are gaining momentum among consumers. Moreover, extensive research investments, increasing healthcare expenses and supportive insurance policies also fuel the U.S. market for insomnia.

Insomnia Market Trends:

Rising Prevalence of Stress, Anxiety, and Mental Health Disorders

The growing incidence of stress, anxiety, and mental health disorders is positively influencing the market. The findings from the American Psychiatric Association's yearly mental health survey for 2024 indicated that US adults experienced heightened anxiety. In 2024, 43% of adults reported feeling more anxious compared to 2023, an increase from 37% in 2023 and 32% in 2022. Modern lifestyles marked by work pressure, digital distractions, and social challenges have led to widespread sleep disturbances. Chronic stress affects hormonal balance and disrupts sleep-wake cycles, resulting in insomnia among both adults and adolescents. Moreover, anxiety and depression often coexist with sleep disorders, increasing the demand for medical interventions. The growing societal awareness around mental well-being has encouraged more individuals to seek professional help, boosting prescriptions for sleep medications and therapies. Pharmaceutical companies are developing safer, non-addictive drugs and cognitive behavioral treatments tailored for stress-related insomnia. As mental health challenges continue to escalate globally, the growing interconnection between psychological wellness and sleep health remains a central factor driving the market expansion.

Growing Aging Population and Higher Risk of Sleep Disorders

The expanding global aging population is significantly contributing to the growth of the insomnia market. As per the WHO, by the year 2030, one in every six individuals will be 60 years old or more across the globe. Older adults are more prone to sleep disturbances due to age-related physiological changes, chronic illnesses, and medication side effects. Conditions, such as arthritis, cardiovascular diseases, and neurological disorders, often interfere with normal sleep patterns. Additionally, melatonin production decreases with age, making it harder for elderly individuals to maintain regular sleep cycles. With longer life expectancy and rising healthcare awareness, more seniors are seeking medical assistance for sleep-related problems. This demographic shift is creating the growing demand for prescription medications, behavioral therapies, and natural sleep aids. Healthcare providers are focusing on holistic sleep management approaches tailored to elderly needs, making age-related sleep disorders one of the key factors driving the market forward.

Increasing Adoption of Digital Lifestyles and Screen Exposure

The growing dependence on digital devices and prolonged screen exposure is offering a favorable market outlook. As per industry reports, by Q3 2024, users globally aged 16 to 64 typically spent 6 hours and 38 minutes each day engaged with screens on different devices. The blue light released by smartphones, tablets, and computers inhibits melatonin secretion, disrupting natural sleep cycles and making it harder to fall asleep. Remote working trends, late-night entertainment, and social media usage have intensified this problem across all age groups. The constant connectivity and overstimulation also contribute to cognitive alertness, preventing adequate rest. As awareness about digital-induced sleep disruption is growing, consumers are turning to sleep aids, mobile applications, and therapies to improve rest quality. Pharmaceutical and wellness companies are addressing this modern lifestyle issue through melatonin-based supplements, behavioral therapies, and mindfulness programs. The continuous expansion of screen-driven lifestyles ensures steady demand for insomnia treatments across both clinical and consumer wellness markets.

Insomnia Industry Segmentation:

Analysis by Therapy Type:

  • Non-Pharmacological Therapy
    • Hypnotherapy
    • Cognitive Behavioral Therapy
    • Medical Devices
    • Others
  • Pharmacological Therapy
    • Prescription Sleep Aids
    • Over-The-Counter Sleep Aids

The pharmacological therapy segment is driven by the increasing demand for effective treatments targeting insomnia's physiological mechanisms and symptomatology. Pharmaceutical innovations aimed at developing medications with improved efficacy and safety profiles play a crucial role in expanding this segment. Research into novel drug formulations and delivery methods, including sustained-release formulations and combination therapies, enhances treatment options. Moreover, the rising prevalence of insomnia globally, exacerbated by lifestyle changes and stressors, amplifies the need for pharmacological interventions that can efficiently address sleep disturbances. Strategic collaborations between pharmaceutical companies and research institutions accelerate drug development processes, driving market competitiveness. Regulatory approvals for new drugs and treatment modalities also stimulate segment growth by expanding market access and enhancing patient trust in therapeutic efficacy.

Analysis by Drug Class:

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Orexin Antagonist
  • Others

Benzodiazepines leads the market with around 28.9% of market share in 2025. The benzodiazepines segment is driven by the increasing demand for effective anxiolytics and sedatives across various medical and psychiatric conditions. Benzodiazepines are favored for their rapid onset of action and efficacy in managing anxiety disorders, insomnia, seizures, and muscle spasms, thereby sustaining their prominence in clinical practice. Moreover, the rising prevalence of anxiety disorders globally, compounded by lifestyle stressors and mental health awareness, fuels insomnia market growth. Additionally, the segment benefits from ongoing research and development efforts aimed at improving drug formulations to minimize side effects and enhance patient compliance. Regulatory approvals for new indications and formulations also bolster market expansion, ensuring broader accessibility and application in diverse healthcare settings. Furthermore, the aging population, particularly in developed regions, contributes significantly as older adults seek treatments for anxiety-related disorders and sleep disturbances.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

The hospital pharmacies segment is driven by the increasing demand for specialized pharmaceutical services within healthcare facilities. These pharmacies play a crucial role in ensuring seamless medication management and distribution within hospitals, catering to inpatient and outpatient needs efficiently. Key drivers include the rising prevalence of chronic diseases requiring complex treatment regimens, which necessitate close coordination between healthcare providers and pharmacists. Additionally, advancements in hospital pharmacy automation and inventory management systems enhance operational efficiency and patient safety.

The retail pharmacies segment is driven by the increasing accessibility and convenience of healthcare services at local community settings. These pharmacies serve as accessible points of care (POC) for routine medication needs, preventive health screenings, and over-the-counter (OTC) products, catering directly to consumer demand. Key drivers include demographic trends such as aging populations requiring ongoing medication management and a shift towards self-care and wellness. Retail pharmacies also benefit from expanding healthcare insurance coverage and regulatory reforms promoting pharmacist-provided clinical services, enhancing their role in primary healthcare delivery.

The drug stores segment is driven by the increasing consumer preference for one-stop shopping experiences that combine pharmaceutical products with convenience goods. These stores offer a wide range of healthcare products, including prescription medications, over-the-counter treatments, and personal care items, appealing to consumers seeking convenience and affordability. Key drivers include strategic partnerships with healthcare providers and pharmaceutical manufacturers, which enhance product offerings and service delivery. Drug stores also benefit from location-based advantages in high-traffic areas and promotional strategies that promote health and wellness solutions.

The online pharmacies segment is driven by the increasing adoption of digital health solutions and e-commerce platforms, facilitating convenient access to medications and healthcare products. These pharmacies offer a diverse range of prescription drugs, over-the-counter medications, and health supplements, often at competitive prices and with home delivery options. Key drivers include the growing consumer demand for telemedicine services, which integrate online consultations with prescription fulfillment, enhancing accessibility and patient convenience. Online pharmacies also benefit from regulatory frameworks supporting virtual healthcare delivery and secure online transactions, ensuring patient safety and data privacy.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 36.4%. The North America regional market is driven by the increasing awareness and diagnosis of insomnia disorders, supported by robust healthcare infrastructure and diagnostic capabilities. The region's high prevalence of lifestyle-related factors such as stress, irregular work hours, and sedentary lifestyles contribute significantly to the rising incidence of sleep disorders. Moreover, the growing elderly population in North America, characterized by a higher susceptibility to insomnia, further propels insomnia market demand. Advances in medical research and technology within the region continuously enhance diagnostic accuracy and treatment efficacy, fostering innovation in therapeutic approaches. Additionally, the proactive regulatory environment and favourable reimbursement policies stimulate market growth by facilitating quicker approvals and broader patient access to treatment options. Collaborative efforts between healthcare providers, pharmaceutical companies, and research institutions drive the development of novel therapies and personalized medicine approaches tailored to address specific patient needs.

Key Regional Takeaways:

United States Insomnia Market Analysis

The United States holds 80.00% of the market share in North America. The United States insomnia market is driven by high stress exposure, demanding work schedules, and lifestyle habits that disrupt sleep cycles across various age groups. Rising mental health burdens, particularly anxiety disorders, occupational burnout, and mood instability, have significantly increased the number of individuals seeking treatment for chronic and acute insomnia. Widespread use of electronic devices, long hours on digital screens, and dependence on mobile-based entertainment late at night are major behavioral drivers, fueling sleep disruption. The country's rapidly aging population is contributing strongly to the market expansion, as seniors frequently experience sleep fragmentation due to chronic illnesses, medication side effects, or neurocognitive decline. The US healthcare system's emphasis on specialized sleep medicine is encouraging growth in sleep labs, polysomnography services, behavioral therapy programs, and telehealth platforms offering digital cognitive behavioral therapy for insomnia (CBT-I). In addition, increasing awareness campaigns around sleep hygiene, productivity loss due to sleep deprivation, and benefits of early intervention are boosting treatment uptake. The pharmaceutical sector plays a central role, supported by extensive research and development activities (R&D) for safer hypnotics, prolonged-release melatonin, orexin receptor antagonists, and non-addictive formulations tailored for long-term use. The health and wellness sector is also stimulating demand through wearable sleep trackers, app-based monitoring solutions, and nutraceutical products, appealing to consumers seeking natural alternatives. As per the IMARC Group, the United States health and wellness market is set to attain USD 1,560 Billion by 2033, exhibiting a CAGR of 5.8% from 2025-2033.

Europe Insomnia Market Analysis

The Europe insomnia market is driven by rising mental health issues, increasing workplace stress, and lifestyle routines that heighten sleep disturbances across both urban and rural populations. The growing awareness about the long-term cognitive and physical effects of poor sleep is encouraging more individuals to seek professional help, expanding demand for behavioral therapies, prescription medicines, and OTC sleep aids. An aging demographic plays a major role, as insomnia prevalence rises with age due to chronic illnesses, pain conditions, and neurological disorders. As per the report published by Age UK, in 2024, there were 22 Million people aged over 50 in England, equivalent to two in five of the total population. Europe's strong regulatory focus on safe and clinically supported treatments is motivating the adoption of non-addictive sleep medications and structured psychological programs like CBT-I. Digital health adoption, including sleep-tracking wearables, mobile apps, and remote therapeutic programs, is gaining traction, as younger consumers are looking for technology-enabled solutions. Additionally, lifestyle factors, such as increased screen exposure, longer working hours, and urban noise pollution, contribute to sleep disruption, further supporting treatment demand.

Asia-Pacific Insomnia Market Analysis

The Asia-Pacific insomnia market is driven by rising stress levels, rapid urbanization, and increasingly demanding work schedules that disrupt sleep patterns across diverse age groups. The growing academic pressure among younger populations and high professional workloads among adults are contributing significantly to insomnia prevalence. Awareness about mental health and sleep quality is improving, encouraging more individuals to explore medical consultations, digital therapeutic tools, and OTC supplements. In October 2025, Go Spiritual, a prominent spiritual organization, initiated a groundbreaking mental health awareness campaign in India on World Mental Health Day. Rooted in the theme 'Harmony in Mind and Soul, this initiative tackled the growing crisis of mental health challenges, suicides, and social pressures by integrating spiritual insights with contemporary mental health approaches. The region's expanding middle class and increasing healthcare access support broader adoption of sleep aids, including herbal remedies, melatonin products, and prescription treatments. Technology use, especially late-night screen exposure, is also a major behavioral factor elevating sleep disturbances. Additionally, aging populations in countries like Japan, South Korea, and China are further boosting the demand.

Latin America Insomnia Market Analysis

The Latin America insomnia market is driven by rising stress, socioeconomic pressures, and increasing mental health concerns that disrupt sleep across different communities. The growing urbanization, long commutes, and extended work hours are contributing to poor sleep hygiene and higher demand for treatment options. Awareness about sleep disorders is gradually improving, encouraging interest in both pharmaceutical therapies and natural supplements. Expanding access to healthcare services and digital wellness tools also supports diagnosis and management. Additionally, lifestyle changes, increased screen usage, and an aging population are propelling the market growth in the region.

Middle East and Africa Insomnia Market Analysis

The Middle East and Africa insomnia market is driven by lifestyle stress, changing work cultures, and environmental factors, such as heat and irregular sleep routines that affect overall rest quality. Rising mental health awareness and better recognition of sleep disorders are encouraging more individuals to seek treatment. Urbanization, late-night technology use, and shift-based employment contribute to widespread sleep disruption. Improving healthcare infrastructure and the growing availability of sleep clinics, medications, and wellness supplements are supporting the market expansion. Additionally, aging population and chronic disease prevalence are driving the demand for insomnia-related solutions.

Competitive Landscape:

Key players in the insomnia market are actively engaged in a variety of strategic initiatives aimed at enhancing their market position and meeting evolving consumer demands. These initiatives include ongoing R&D efforts focused on discovering and developing new pharmacological treatments and therapies tailored to address different types and severities of insomnia. Additionally, players are investing in advanced diagnostic technologies to improve the accuracy of insomnia diagnosis, thereby enabling more personalized treatment approaches. Collaborations with healthcare providers and academic institutions are also common, facilitating the exchange of knowledge and the development of innovative treatment protocols. Furthermore, there is a growing emphasis on the integration of digital health solutions and telemedicine platforms to expand access to insomnia care and improve patient outcomes through remote monitoring and support services. Players are also navigating regulatory landscapes to secure approvals for new products and indications, ensuring compliance with evolving healthcare regulations. Market leaders are increasingly focused on sustainability and social responsibility initiatives, aligning their business strategies with broader environmental and community health goals.

The report provides a comprehensive analysis of the competitive landscape in the insomnia market with detailed profiles of all major companies, including:

  • Aurobindo Pharma USA
  • Eisai Inc.
  • Idorsia Pharmaceuticals, Ltd
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc
  • Neurim Pharmaceuticals LTD
  • Pfizer Inc
  • Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the insomnia market?
  • 2.What is the future outlook of insomnia market?
  • 3.What are the key factors driving the insomnia market?
  • 4.Which region accounts for the largest insomnia market share?
  • 5.Which are the leading companies in the global insomnia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Insomnia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Non-Pharmacological Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Hypnotherapy
      • 6.1.2.2 Cognitive Behavioral Therapy
      • 6.1.2.3 Medical Devices
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Pharmacological Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Prescription Sleep Aids
      • 6.2.2.2 Over-The-Counter Sleep Aids
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Antidepressants
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Melatonin Antagonist
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Benzodiazepines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Nonbenzodiazepines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Orexin Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Drug Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Online Pharmacies
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aurobindo Pharma USA
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Eisai Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Idorsia Pharmaceuticals, Ltd
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Mallinckrodt Pharmaceuticals
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Merck & Co., Inc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Neurim Pharmaceuticals LTD
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Pfizer Inc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi S.A.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Insomnia Market: Major Drivers and Challenges
  • Figure 2: Global: Insomnia Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Insomnia Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Insomnia Market: Breakup by Therapy Type (in %), 2025
  • Figure 5: Global: Insomnia Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Insomnia Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Insomnia Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Insomnia (Non-Pharmacological Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Insomnia (Non-Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Insomnia (Pharmacological Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Insomnia (Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Insomnia (Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Insomnia (Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Insomnia (Melatonin Antagonist) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Insomnia (Melatonin Antagonist) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Insomnia (Benzodiazepines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Insomnia (Benzodiazepines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Insomnia (Nonbenzodiazepines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Insomnia (Nonbenzodiazepines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Insomnia (Orexin Antagonist) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Insomnia (Orexin Antagonist) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Insomnia (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Insomnia (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Insomnia (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Insomnia (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Insomnia (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Insomnia (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Insomnia (Drug Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Insomnia (Drug Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Insomnia (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Insomnia (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Insomnia Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Insomnia Industry: SWOT Analysis
  • Figure 82: Global: Insomnia Industry: Value Chain Analysis
  • Figure 83: Global: Insomnia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Insomnia Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Insomnia Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
  • Table 3: Global: Insomnia Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Insomnia Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Insomnia Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Insomnia Market: Competitive Structure
  • Table 7: Global: Insomnia Market: Key Players